TrialSignal
Clinical trial intelligence report
A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 16, 2026
NCT ID
NCT00049517
Status
COMPLETED
Phase
Phase 3
Sponsor
Eastern Cooperative Oncology Group
Executive brief
Investment-Ready Snapshot
This Phase 3 trial sponsored by the Eastern Cooperative Oncology Group investigates the efficacy of a combination chemotherapy regimen followed by autologous stem cell transplantation in adult patients with acute myeloid leukemia (AML). The trial's outcomes could significantly impact treatment protocols for AML, a market projected to grow due to increasing incidence rates and advancements in therapeutic options. The inclusion of gemtuzumab ozogamicin, a monoclonal antibody, may provide a competitive edge if proven effective, particularly against standard chemotherapy regimens. Companies involved in AML therapies should monitor the results closely for potential shifts in treatment paradigms and market opportunities.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00049517
Indication
Leukemia
Modality
protein therapy
Target
Combination chemotherapy with daunorubicin and cytarabine, with potential addition of gemtuzumab ozogamicin targeting CD33 in acute myeloid leukemia (AML).
Intervention
sargramostim, busulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (GO), Daunorubicin, Autologous HCT, Allogeneic HCT
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.